Keep pulling the thread on Albert Bourla.
Following its financial success from COVID-19 products, Pfizer invested over $80 billion in acquisitions.
Pfizer's revenue from COVID-19 products decreased from $56 billion in 2022 to $6 billion in 2023.
Pfizer acquired Seagen for over $40 billion primarily to gain its leading technology in Antibody-Drug Conjugates (ADCs).
Pfizer had to discontinue two of its own major obesity drug candidates due to signs of liver toxicity.
Phase II clinical data for Pfizer's acquired obesity drug candidate has confirmed its potential as a monthly injectable treatment, which would compete against weekly products from Eli Lilly and Novo Nordisk.
China's 14th Five-Year Plan includes a strategic goal to develop globally competitive pharmaceutical companies by 2035-2036.
According to the 2025 Nature Index, 8 of the top 10 universities for scientific output were Chinese, a significant shift from previous years when 8 of the top 10 were typically from the United States.
Albert Bourla predicts that China's pharmaceutical research and development capabilities will surpass those of the United States within one to two years.
Albert Bourla asserts that emerging Chinese pharmaceutical companies operate at half the cost and three times the speed of established Western competitors.
Albert Bourla believes Western pharmaceutical companies have approximately five years to fundamentally transform their operations to compete with the efficiency of emerging Chinese firms.
Albert Bourla claims that US drug pricing policies have led to the pharmaceutical industry trading at its lowest historical valuation multiple in 2025, thereby reducing investment capital available for the biotech sector.
Albert Bourla is very optimistic about the scientific progress that will be seen in the pharmaceutical industry by the end of the decade.